Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dichloroacetate.

P W Stacpoole1, Y J Greene

  • 1Department of Medicine (Division of Endocrinology and Metabolism), University of Florida, College of Medicine, Gainesville 32610.

Diabetes Care
|June 1, 1992
PubMed
Summary
This summary is machine-generated.

Dichloroacetate (DCA) is a potential oral antidiabetic drug that lowers blood glucose and lipids by inhibiting glucose production and enhancing glucose utilization. DCA shows promise for managing diabetes by targeting key metabolic pathways.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Haplotype variations in glutathione transferase zeta 1 influence the kinetics and dynamics of chronic dichloroacetate in children.

Journal of clinical pharmacology·2014
Same author

Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors.

Investigational new drugs·2013
Same author

Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells.

Gene therapy·2011
Same author

Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial.

Neurology·2006
Same author

Metabolic complications of severe malaria.

Current topics in microbiology and immunology·2005
Same author

Effects of alginate encapsulation on mitochondrial activity.

Journal of materials science. Materials in medicine·2005
Same journal

A Secular Increase in the Incidence of Islet Autoimmunity Among Colorado Children With Moderate-Risk HLA Genotypes.

Diabetes care·2026
Same journal

Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor-Induced Diabetes With Seroconversion of GAD Antibodies.

Diabetes care·2026
Same journal

State Insulin Out-of-Pocket Cap Policies and Estimated Eligible Populations in the United States, 2019-2026.

Diabetes care·2026
Same journal

Genetic Determinants of Macronutrient Intake Are Associated With Specific Food Intake in Youth: A Cohort Study Across Childhood and Adolescence.

Diabetes care·2026
Same journal

A Novel Electronic Medical Record Search Method to Identify Patients With Ketosis-Prone Diabetes: Implications for Discovery of Atypical Diabetes.

Diabetes care·2026
Same journal

Real-Time Continuous Glucose Monitoring Among People With Type 2 Diabetes and End-Stage Kidney Failure Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial.

Diabetes care·2026
See all related articles

Area of Science:

  • Biochemistry
  • Pharmacology
  • Endocrinology

Background:

  • Dichloroacetate (DCA) is explored as a novel oral antidiabetic agent.
  • It functions independently of insulin secretion, targeting glucose and lipid metabolism.

Purpose of the Study:

  • To evaluate the efficacy of Dichloroacetate (DCA) in managing hyperglycemia and dyslipidemia.
  • To investigate the metabolic mechanisms underlying DCA's antidiabetic effects.

Main Methods:

  • Studies involved experimental models of ketosis and diabetes (both insulin-dependent and non-insulin-dependent).
  • Assessed effects on hepatic glucose synthesis, glucose clearance, pyruvate dehydrogenase (PDH) activity, and lipid biosynthesis.
  • Clinical short-term studies in diabetic patients were conducted.

Related Experiment Videos

Main Results:

  • DCA inhibits hepatic glucose synthesis and enhances peripheral glucose utilization.
  • It stimulates pyruvate dehydrogenase (PDH), reducing gluconeogenesis precursors.
  • DCA lowers blood glucose, ketonemia, ketonuria, and inhibits hepatic triglyceride and cholesterol synthesis.
  • In patients, DCA reduced VLDL cholesterol and triglyceride levels; in models, it lowered insulin requirements and blood glucose/triglycerides.

Conclusions:

  • Dichloroacetate (DCA) demonstrates significant potential in managing both glucose and lipid abnormalities associated with diabetes.
  • Further research is necessary to establish the safety and efficacy of DCA and its derivatives for long-term human use in diabetes treatment.